BDC-1001 is an investigational Immune-Stimulating Antibody Conjugate (ISAC) in development for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive cancer.
The ESMO presentation will include new results from the recently completed study in patients with advanced HER2-expressing solid tumors.
The company’s Boltbody ISAC platform harnesses the precision of antibodies with the immune system to reprogram the tumor microenvironment to generate a ‘productive’ anti-cancer response.
Each Boltbody ISAC candidate comprises a tumor-targeting antibody, a non-cleavable linker and a proprietary immune stimulant.
Following the completion of the dose-escalation trial, Bolt is now conducting two phase 2 clinical trials in the US, Europe, and South Korea – for patients with colorectal, endometrial and gastroesophageal cancers, as well as patients with breast cancer.
Edith Perez, chief medical officer of Bolt Biotherapeutics, said: “The upcoming presentation at ESMO builds on the positive data we presented at ASCO 2023 with additional insights into efficacy, safety, and biomarkers. These data provide further support for the recommended phase 2 dose (RP2D) being used in the ongoing phase 2 study of BDC-1001."
"We are proud of the significant progress we have made with BDC-1001 and these latest data reinforce that Boltbody ISACs can activate a patient’s immune system to fight cancer. We continue to advance BDC-1001 through the Phase 2 clinical studies in four HER2-positive solid tumor types.”